CD BioSciences announced the release of its whole genome sequencing services to support exploring genome function and systematic evolution. New York, USA – January 31, 2023 – Drosophila Center, the
Creative Bioarray announced the release of its wide range of iPSC differentiation kits to support iPS cell differentiation. New York, USA – January 31, 2023 – Creative Bioarray, one of
Creative Bioarray announced the release of its autophagy detection services to support cell growth and development. New York, USA – January 31, 2023 – Cell Assay platform, the division of
Veteran Actor Ruben Rabasa to Attend World Premiere of Marvel’s “Ant-Man and the Wasp: Quantumania” in Hilarious Role as Café Owner. Fans of the iconic sketch comedy series “I Think
Many patients suffering from issues like enlarged prostate, chronic prostatitis, prostate cancer and other genitourinary diseases have been able to find relief at 3D Urology and Prostate Clinics. The number
The global smart meters market size is expected to grow from an estimated USD 19.6 billion in 2021 to USD 30.2 billion by 2026, at a CAGR of 9.0% during
DelveInsight’s, “COVID-19 Pipeline Insight, 2023,” report provides comprehensive insights about 400+ companies and 400+ pipeline drugs in COVID-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical
DelveInsight’s, “CRISPR Therapies Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles,
DelveInsight’s, “Post-Traumatic Stress Disorder Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Post-Traumatic Stress Disorder pipeline landscape. It covers the pipeline drug
DelveInsight’s, “Migraine Pipeline Insight, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including Migraine clinical
DelveInsight’s, “Thyroid Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug
Jan 30, 2023 – New York, NY – The next generation real-time live virtual events and concerts metaverse platform company STGZ, announced a partnership with Klaytn, a global metaverse public
iZenBridge is a leading training and coaching worldwide platform to develop skilled professionals by offering top industry-demand courses on Lean, Agile, Coaching, Project Management, and other related topics. iZenBridge is
DelveInsight’s, “Acute Kidney Injury Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Acute Kidney Injury pipeline landscape. It covers the pipeline drug
DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the pipeline
DelveInsight’s, “Dry Age-Related Macular Degeneration Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Dry Age-Related Macular Degeneration pipeline landscape. It covers the pipeline
DelveInsight’s, “Relapsed/refractory Acute Myeloid Leukemia Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the
DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight, 2022,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the
DelveInsight’s, “Urothelial Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including Urothelial
DelveInsight’s, “Neuroblastoma Pipeline Insight, 2023,” report provides comprehensive insights about 35+ Neuroblastoma companies and 35+ pipeline drugs in Neuroblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and
